Attached files
| file | filename |
|---|---|
| 10-Q/A - 10-Q/A - Assertio Therapeutics, Inc | a15-23793_110qa.htm |
| EX-10.2 - EX-10.2 - Assertio Therapeutics, Inc | a15-23793_1ex10d2.htm |
| EX-10.1 - EX-10.1 - Assertio Therapeutics, Inc | a15-23793_1ex10d1.htm |
| EX-10.3 - EX-10.3 - Assertio Therapeutics, Inc | a15-23793_1ex10d3.htm |
| EX-31.2 - EX-31.2 - Assertio Therapeutics, Inc | a15-23793_1ex31d2.htm |
| EX-10.4 - EX-10.4 - Assertio Therapeutics, Inc | a15-23793_1ex10d4.htm |
| EX-10.5 - EX-10.5 - Assertio Therapeutics, Inc | a15-23793_1ex10d5.htm |
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James A. Schoeneck, certify that:
1. I have reviewed this Amendment No. 1 to Quarterly Report on Form 10-Q/A of Depomed, Inc.; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
|
December 18, 2015 |
|
|
|
|
|
|
|
|
By: |
/s/ James A. Schoeneck |
|
|
|
James A. Schoeneck |
|
|
|
Chief Executive Officer |